Celldex Therapeutics Completes Acquisition of CuraGen Corporation for $93.5 Million
On October 1, Celldex Therapeutics, Inc. announced the successful completion of its acquisition of CuraGen Corporation. The purchase price for CuraGen was approximately $93.5 million and, as a result of the merger, CuraGen has become a wholly owned subsidiary of Celldex. The acquisition adds a portfolio of oncology-focused, fully-owned antibodies to Celldex's Precision Targeted Immunotherapy Platform.
WilmerHale represented CuraGen in this transaction. The WilmerHale team included Lara Mataac and Ravi Faiia from the Corporate Group, and
Kimberly Wethly from the Tax Group. William Schmidt advised on employee benefits,
Sally Byrne advised on licensing and
Michael Twomey advised on patent matters.
